Cbd Life Science Stock Price, News & Analysis

CBD Life Sciences (CBDL) has announced the launch of a new 500MG Delta-8 THC gummy product, expanding its cannabinoid wellness portfolio. The lab-tested gummies, available in Blue Razz & Strawberry flavors, are manufactured in-house and will be sold through www.thecbdvault.com. The product launch aligns with growing Delta-8 market projections, expected to reach $2.1 billion by 2026.

The gummies are designed to offer various wellness benefits, including pain relief, anxiety and stress support, nausea control, appetite stimulation, and potential neuroprotective effects. Unlike Delta-9 THC, Delta-8 provides a milder psychoactive experience. Each batch undergoes independent lab testing to ensure purity, potency, and compliance.

CBD Life Sciences Inc. (CBDL) has announced a strategic manufacturing partnership with Jeannie in a Bottle, an Arizona-based CBD company. Under this agreement, CBDL will handle the production, packaging, and labeling of high-potency CBD products exclusively for Jeannie in a Bottle, which has a presence in over 100 gas stations and convenience stores across the United States.

The partnership leverages Jeannie in a Bottle's established retail network while utilizing CBDL's manufacturing capabilities. This collaboration is expected to generate consistent monthly reorders and strengthen CBDL's revenue pipeline through ongoing production contracts. The deal strategically positions CBDL to expand its national presence in the growing CBD wellness market through the convenience store and gas station retail channel.

CBD Life Sciences has secured a strategic manufacturing partnership with Thallos, a Colombian company, to produce high-potency CBD products for the South American market. The deal positions CBDL to tap into the $4.9 billion Latin American CBD market.

Under the agreement, CBDL will manufacture Thallos' product line including:

• 2,000mg Pain Cream Salve (Mint and Cinnamon varieties)
• 2,000mg CBD Tincture

Production will take place at CBDL's U.S. facilities, offering Thallos a solution to bypass tariff and regulatory challenges for CBD imports. CEO Lisa Nelson describes the partnership as a "game-changer," positioning CBDL as a key player in the global CBD supply chain. The deal promises recurring revenue streams and strengthens CBDL's international market presence.

CBD Life Sciences Inc. (OTC:CBDL) has launched a groundbreaking 100MG Full Spectrum CBD Gummy targeting mental health and focus. The product, available in Crisp Green Apple and Wild Blueberry flavors, is positioned as a natural alternative for mental clarity and emotional well-being.

The launch comes as the global CBD market is projected to exceed $60 billion by 2030, with the mental wellness industry surpassing $500 billion. The company's CEO, Lisa Nelson, emphasizes this product's role in addressing mental health challenges without pharmaceutical side effects.

Key features include:

• Lab-tested formulation with verified Certificates of Analysis (COAs)
• Full-spectrum cannabinoids for enhanced effectiveness
• Target audience includes entrepreneurs, creatives, students, and professionals

The company is currently in preliminary discussions with wellness clinics and mental health centers for potential integration into patient routines, though no formal agreements have been established.

CBD Life Sciences Inc. (CBDL) has reported a remarkable 500% increase in online sales for Q1 2025, marking significant growth in the wellness sector. The company has expanded beyond traditional CBD products, introducing wellness formulations that include Reishi, Lion's Mane, and Ashwagandha adaptogens.

Key developments include:

• Launch of CBD Kava & Kratom Shots as natural alternatives to caffeine
• Expansion to Walmart Marketplace and DoorDash platforms
• Implementation of proprietary Nano-CBD Technology
• Focus on US-made, third-party tested products with clean-label ingredients

The company is positioning itself at the intersection of the CBD market (projected to exceed $60 billion by 2030) and the functional mushroom market (expected to reach $24 billion by 2032). Their top-selling products include 3000MG Pain Relief Cream, CBD Kava & Kratom Shots, and Mushroom Wellness Blends.

CBD Life Sciences Inc. (CBDL) announces its strategic expansion into the functional mushroom market, which is projected to reach $19.3 billion by 2030. The company is focusing on brain-boosting mushroom applications, particularly utilizing Lion's Mane (Hericium erinaceus) for its cognitive enhancement properties.

Recent research from the University of Queensland has identified compounds in mushrooms that promote nerve growth and enhance memory. CBDL plans to develop wellness products targeting brain function, learning ability, and neuroprotection against age-related decline.

The company emphasizes its commitment to safety and regulatory compliance, developing non-psychedelic mushroom compounds with strict quality control measures. This expansion represents CBDL's strategic pivot beyond CBD and cannabis, positioning itself in the broader alternative wellness space with potential for multiple revenue streams across health, sustainability, and technology sectors.

CBD Life Sciences Inc. (CBDL) has launched Passion Fuel Cordyceps Complex, a natural sexual enhancement supplement, targeting the growing sexual wellness market projected to exceed $125 billion by 2026. The product contains 300mg of pure Cordyceps extract per serving, designed to enhance libido, stamina, and overall performance.

The supplement offers multiple benefits including improved erectile function, boosted athletic performance, enhanced blood flow, optimized hormonal balance, and increased energy levels. According to CEO Lisa Nelson, this launch represents a strategic milestone for CBDL as they expand their product line with science-backed formulations.

The company plans to distribute Passion Fuel through major online marketplaces, wellness retailers, and direct-to-consumer platforms, while exploring global strategic partnerships. This launch aligns with CBDL's expansion strategy in the dietary supplement market, which exceeded $177 billion in 2023.

CBD Life Sciences Inc. (CBDL) announces its participation in the upcoming Cave Creek Bike Week from March 28 - April 6, 2025. The event, which runs parallel to Arizona Bike Week, historically attracts around 85,000 attendees and generates approximately $20 million in local economic impact.

CBDL's subsidiary, Mushroom Madness, will showcase its product line at the Horny Toad Restaurant location, featuring:

• 3000MG CBD Pain Relief Cream (available on Walmart Marketplace)
• Mellow Mornings CBD Coffee Creamer with nano-CBD technology
• Functional Mushroom Supplements with Reishi, Lion's Mane, and Ashwagandha
• Kava & Kratom Energy Shots

CEO Lisa Nelson views the event as a significant revenue opportunity, targeting motorcycle enthusiasts and wellness-focused consumers. The company aims to leverage this high-traffic event to boost direct-to-consumer sales and enhance brand visibility.